Please ensure Javascript is enabled for purposes of website accessibility

Insulet Announces Agreements With Abbott and DexCom

By Jim Crumly - Feb 19, 2020 at 2:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Insulet's wearable insulin pumps will be integrated with blood glucose monitors from both companies.

On Wednesday, insulin pump maker Insulet (PODD -0.50%) announced agreements with Abbott (ABT 0.31%) and DexCom (DXCM 1.97%), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. Shares of Insulet were up by more than 2% on the news as of 2 p.m. EST.

The integrated systems will allow patients to have their insulin delivery controlled automatically according to their blood glucose levels using disposable CGMs and Insulet's wearable, tubeless insulin delivery pods. The systems will use Insulet's Omnipod Horizon system, which it expects to launch in the second half of 2020.

Blood sugar control chart and test tube of blood.

Image source: Getty Images.

The increasing cooperation between Insulet and DexCom on an integrated system should come as little surprise, as the companies had already announced their partnership as part of Insulet's development program for Horizon, which is in a pivotal trial with up to 240 participants. Wednesday's press release announced a commercialization agreement between the companies, but the terms were not disclosed.

The bigger news regarded the agreement with Abbott. The Horizon system was designed to work with multiple sensors, and although Abbott was the logical choice as a second partner, Insulet hadn't previously confirmed the companies were working on an integrated product.

Abbott's FreeStyle Libre CGM is the market leader, and could be more important to Insulet's business than DexCom's devices. Core to the growth strategy of the rapidly expanding diabetes company is international expansion, and the massive Abbott already has 2 million FreeStyle Libre users in 46 countries.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$111.83 (0.31%) $0.34
DexCom, Inc. Stock Quote
DexCom, Inc.
$91.60 (1.97%) $1.77
Insulet Corporation Stock Quote
Insulet Corporation
$269.36 (-0.50%) $-1.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.